Definium Therapeutics

Corporate brand

Definium Therapeutics (formerly MindMed) is a science-led company developing psychedelic medicine, with a lead clinical program DT120 ODT targeting MDD, GAD, and PTSD. An American biopharmaceutical company developing psychedelic and psychoplastogenic medicines. Definium Therapeutics (formerly MindMed) is an American clinical-stage biopharmaceutical company developing psychedelic and psychoplastogenic medicines, with a lead program DT120 (formerly MM120), an LSD-based formulation for generalized anxiety disorder.

Last updated October 30, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Definium Therapeutics, formerly MindMed, describes itself as science-led and evidence-backed, harnessing the therapeutic potential of psychedelic medicine to develop accessible treatments for brain health disorders. The company is revisiting LSD through a modern lens and its strategy focuses on major depressive disorder (MDD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). Its lead clinical program, DT120 ODT, has four phase 3 studies and a fifth planned in PTSD. Definium Therapeutics was founded in 2019. Definium Therapeutics, Inc. is an American biopharmaceutical company headquartered in New York and focused on the clinical development of psychedelic and broader psychoplastogenic medicines. The company was founded in May 2019 by Stephen Hurst and Jamon Rahn under the name MindMed. It initially concentrated on 18-MC, a non-hallucinogenic molecule derived from ibogaine research, with the aim of developing treatments for opioid withdrawal and opioid use disorder. In June 2019, MindMed acquired the 18-MC development program, which had previously received support from the U.S. National Institute on Drug Abuse, and later began preparing the compound for a Phase I clinical trial. MindMed expanded beyond the 18-MC program as interest in psychedelic-assisted treatment and psychedelic pharmacology grew. Its research portfolio came to include LSD-related medicines, psilocybin, DMT, MDMA, and compounds intended to make psychedelic treatments more practical for clinical use. A central objective was to develop medicines with controlled dosing, predictable effects, and treatment protocols suitable for regulated medical settings rather than relying solely on traditional or investigator-led psychedelic use. The company pursued academic and clinical partnerships to support this strategy. In 2020, it announced a partnership with NYU Langone to establish a training and research program for psychiatrists working with psychedelic therapies. MindMed committed funding to the initiative, which was also intended to investigate psychedelic medicines in areas including alcohol-use disorder. The company also entered a long-term relationship with the Liechti Lab at University Hospital Basel, obtaining access to extensive research data concerning LSD, MDMA, and other psychoactive substances. Additional academic work involved Maastricht University, where a Phase I study examined the effects of low doses of LSD on mood, sleep, and neuroplasticity. MindMed became notable as one of the earliest dedicated psychedelic pharmaceutical companies to access public capital markets. It completed a reverse takeover with Canadian gold-mining company Broadway Gold Mining and began trading on the Canadian NEO Exchange in March 2020. The company subsequently received approval to move from the OTC Markets to Nasdaq, where it began trading under the symbol MNMD in April 2021. This listing helped make the company a visible participant in the emerging public-market psychedelic-medicine sector, although it also exposed the business to the financing, regulatory, clinical, and valuation risks common to development-stage biotechnology companies. Leadership changed in 2021 when co-founder Jamon Rahn stepped down as chief executive officer and as a board director. Robert Barrow, then the company’s chief development officer, became chief executive. MindMed also completed the acquisition of digital-health company HealthMode in February 2021. Daniel Karlin, M.D., HealthMode’s chief executive, joined MindMed as chief medical officer, strengthening the company’s clinical-development and digital-trial capabilities. The company’s most prominent clinical program became MM120, a pharmaceutical formulation of LSD, now referred to as DT120. In August 2022, the first participant was dosed in a Phase 2b study evaluating MM120 in generalized anxiety disorder. The trial enrolled 198 participants, and reported results indicated statistically significant improvement for many participants. In March 2024, the U.S. Food and Drug Administration granted the program breakthrough therapy designation for generalized anxiety disorder, an important regulatory milestone intended to facilitate development and review of medicines addressing serious conditions with preliminary evidence of substantial benefit. On January 12, 2026, MindMed adopted the Definium Therapeutics name. Under the new identity, the company continues to present itself as a clinical-stage biopharmaceutical business developing psychedelic and psychoplastogenic treatments. Publicly described work includes DT120 in anxiety-related indications and broader research into compounds and treatment approaches that may offer therapeutic neuroplasticity with improved duration, safety, tolerability, and clinical control. As a development-stage company, its ultimate commercial position remains dependent on clinical results, regulatory approvals, manufacturing, financing, and the ability to translate experimental psychedelic pharmacology into scalable medical products. Definium Therapeutics, Inc., formerly MindMed, is an American biopharmaceutical company headquartered in New York and focused on the clinical development of psychedelic and broader psychoplastogenic medicines. Founded in May 2019 by Stephen Hurst and Jamon Rahn, it initially concentrated on 18-MC, a non-hallucinogenic molecule derived from ibogaine research, targeting opioid withdrawal and opioid use disorder. It later broadened its portfolio to LSD-related medicines, psilocybin, DMT, MDMA, and compounds intended to make psychedelic treatments more practical for regulated clinical use. The company became one of the first psychedelic-focused pharmaceutical companies to list publicly, via a reverse takeover with Broadway Gold Mining on the Canadian NEO Exchange in March 2020, and began trading on Nasdaq under MNMD in April 2021. Its lead clinical program, DT120 ODT (formerly MM120), has four phase 3 studies and a fifth planned in PTSD; the program received FDA breakthrough therapy designation for generalized anxiety disorder in March 2024. MindMed adopted the Definium Therapeutics name on January 12, 2026.

History

Definium Therapeutics was founded in 2019. The company states that its roots date back further, and that it is revisiting psychedelics through a modern lens. It describes its approach as starting with a decades-old molecule and advancing it with today's clinical, manufacturing, regulatory, and scientific standards. The company is retracing LSD to its origins and unlocking its clinical promise as a transformative therapeutic. Definium Therapeutics was founded as MindMed in May 2019 by Stephen Hurst and Jamon Rahn. Its original focus was 18-MC, a non-hallucinogenic molecule associated with ibogaine research and investigated as a potential treatment for opioid withdrawal and opioid use disorder. In June 2019, the company acquired the 18-MC development program, which had previously been supported by the U.S. National Institute on Drug Abuse. MindMed began preparing the program for a Phase I FDA clinical trial later that year. The company subsequently broadened its scope to include LSD, psilocybin, DMT, MDMA, and other psychedelic or psychoplastogenic approaches. In March 2020, it partnered with NYU Langone on a program intended to train psychiatrists and advance clinical research in psychedelic therapies. The initiative also contemplated research involving 18-MC and psilocybin-assisted treatment for alcohol-use disorder. In April 2020, MindMed entered a long-term partnership with the Liechti Lab at University Hospital Basel, gaining access to more than a decade of research data involving LSD, MDMA, and related substances. Work connected with the lab included studies of LSD dosing, comparisons between LSD and psilocybin, DMT research, and concepts for controlling or shortening psychedelic experiences in therapeutic settings. MindMed also entered an investigator-sponsored study agreement with Maastricht University in December 2020. The resulting Phase I work evaluated low doses of LSD in relation to mood, sleep, and neuroplasticity. Research results from the Liechti collaboration were later reported in scientific and conference settings, including comparative observations concerning LSD and psilocybin and the effects of psychedelics following antidepressant treatment. MindMed became one of the first psychedelic-focused pharmaceutical companies to list publicly. It completed a reverse takeover with Broadway Gold Mining and began trading on the Canadian NEO Exchange in March 2020. After approval to uplist from the OTC Markets, it began trading on Nasdaq under MNMD in April 2021. In February 2021, MindMed completed its acquisition of HealthMode, a digital-health company, and appointed HealthMode chief executive Daniel Karlin as chief medical officer. In June 2021, co-founder and chief executive Jamon Rahn left both the CEO role and the board; chief development officer Robert Barrow became CEO. The company’s leading clinical program became MM120, an LSD-based formulation later known as DT120. The first patient in a Phase 2b generalized anxiety disorder trial was dosed in August 2022. The study enrolled 198 participants and reported significant improvements for many subjects. In March 2024, the FDA granted MM120 breakthrough therapy designation for generalized anxiety disorder. On January 12, 2026, MindMed rebranded as Definium Therapeutics. The renamed company remains focused on advancing clinical applications of psychedelic and psychoplastogenic medicines, while its future depends on clinical validation, regulatory approval, financing, manufacturing, and commercialization. The company subsequently broadened its scope to include LSD, psilocybin, DMT, MDMA, and other psychedelic or psychoplastogenic approaches. In March 2020, it partnered with NYU Langone on a program intended to train psychiatrists and advance clinical research in psychedelic therapies; the initiative also contemplated research involving 18-MC and psilocybin-assisted treatment for alcohol-use disorder. In April 2020, MindMed entered a long-term partnership with the Liechti Lab at University Hospital Basel, gaining access to more than a decade of research data involving LSD, MDMA, and related substances. Work connected with the lab included studies of LSD dosing, comparisons between LSD and psilocybin, DMT research, and concepts for controlling or shortening psychedelic experiences in therapeutic settings. In December 2020, MindMed entered an investigator-sponsored study agreement with Maastricht University; the resulting Phase I work evaluated low doses of LSD in relation to mood, sleep, and neuroplasticity. Research results from the Liechti collaboration were later reported in scientific and conference settings, including comparative observations concerning LSD and psilocybin and the effects of psychedelics following antidepressant treatment.

2026
Rebrand to Definium Therapeutics
[4]Definium Therapeuticsen.wikipedia.org
On January 12, 2026, MindMed changed its corporate name to Definium Therapeutics.
2024
Breakthrough therapy designation
[4]Definium Therapeuticsen.wikipedia.org
The FDA granted breakthrough therapy designation to MM120 for generalized anxiety disorder in March 2024.
2022
Phase 2b MM120 trial begins
[4]Definium Therapeuticsen.wikipedia.org
The first participant was dosed in the generalized anxiety disorder study of MM120, later called DT120; the 198-participant study reported statistically significant improvement for many participants.
2021
Nasdaq trading begins
[4]Definium Therapeuticsen.wikipedia.org
MindMed began trading on Nasdaq under the ticker MNMD in April 2021 after an uplisting from the OTC Markets.
2020
Public listing on the Canadian NEO Exchange
[4]Definium Therapeuticsen.wikipedia.org
The company became public through a reverse takeover with Broadway Gold Mining and began trading on the Canadian NEO Exchange in March 2020.
2019
Company founded as MindMed
[4]Definium Therapeuticsen.wikipedia.org
Stephen Hurst and Jamon Rahn founded MindMed in May 2019.
2019
18-MC development program acquired
[4]Definium Therapeuticsen.wikipedia.org
MindMed acquired the 18-MC program, previously supported by the U.S. National Institute on Drug Abuse, and began preparing it for an FDA Phase I trial targeting opioid-related disorders.

Products and positioning

Science-led and evidence-backed developer of psychedelic medicine for brain health disorders. A clinical-stage psychedelic-medicine biotechnology company seeking to convert psychedelic and psychoplastogenic compounds into standardized, regulated treatments.

Investigational psychedelic medicine
DT120 ODT
Lead clinical program with four phase 3 studies, and a fifth planned in PTSD. DT120, formerly designated MM120, is an investigational pharmaceutical formulation of LSD being developed for psychiatric indications, most prominently generalized anxiety disorder. The program is intended to provide a standardized, clinically controlled form of psychedelic treatment rather than an unregulated or purely research-use experience. A Phase 2b study began dosing in 2022, and the program received FDA breakthrough therapy designation in 2024. The lead clinical program has four phase 3 studies, and a fifth is planned in PTSD. It remains an investigational product and is not described here as an approved medicine.
Investigational psychedelic medicine · 2022
DT120
DT120, formerly designated MM120, is an investigational pharmaceutical formulation of LSD being developed for psychiatric indications, most prominently generalized anxiety disorder. The program is intended to provide a standardized, clinically controlled form of psychedelic treatment rather than an unregulated or purely research-use experience. A Phase 2b study began dosing in 2022, and the program received FDA breakthrough therapy designation in 2024. It remains an investigational product and is not described here as an approved medicine.
Investigational non-hallucinogenic ibogaine-related compound · 2019
18-MC
18-MC was the company's initial development focus after MindMed acquired the program in 2019. The non-hallucinogenic molecule is based on research associated with ibogaine and was being prepared for clinical investigation in opioid withdrawal and opioid use disorder. The available reference material does not establish a current development status or commercial availability.

Marketing campaigns

2020NYU Langone psychedelic medicine training partnership
United States
MindMed partnered with NYU Langone to support psychiatrist training and research in psychedelic therapies, with related work proposed in areas including alcohol-use disorder. The partnership established an academic and clinical-training initiative; the available material does not provide a complete later outcome.
Outcome. The partnership established an academic and clinical-training initiative; the available material does not provide a complete later outcome.
Source

Brand decisions

2026
Corporate rebrand to Definium TherapeuticsStrategy
Background
The company continued developing psychedelic and psychoplastogenic medicines under its former MindMed identity.
Action taken
MindMed adopted the Definium Therapeutics name.
Aftermath
The company continued operating as a development-stage biopharmaceutical business under the Definium Therapeutics identity.
Source
2022
Phase 2b development of MM120Product launch
Background
MindMed was developing an LSD-based medicine for generalized anxiety disorder.
Action taken
The first patient was dosed in a Phase 2b trial of MM120.
Aftermath
The 198-participant study reported statistically significant improvement for many participants and supported further clinical development.
Source
2021
HealthMode acquisitionM&A
Background
MindMed sought digital-health capabilities to support clinical development and research.
Action taken
The company completed its acquisition of HealthMode and appointed Daniel Karlin as chief medical officer.
Aftermath
The transaction expanded MindMed's clinical and digital-trial capabilities.
Source
2020
Reverse takeover used to access public marketsM&A
Background
MindMed sought a public listing while operating as a development-stage psychedelic biotechnology company.
Action taken
It completed a reverse takeover with Canadian gold-mining company Broadway Gold Mining and listed on the Canadian NEO Exchange.
Aftermath
The transaction made MindMed one of the first psychedelic-focused pharmaceutical companies to become publicly traded.
Source

Recent events

2026
MindMed rebrands as Definium Therapeutics[4]Definium Therapeuticsen.wikipedia.org
Other
MindMed adopted the Definium Therapeutics name as part of a corporate rebrand.
2024
FDA grants breakthrough therapy designation to MM120[4]Definium Therapeuticsen.wikipedia.org
Regulation
The U.S. FDA granted breakthrough therapy designation to MindMed’s LSD-derived MM120 program for generalized anxiety disorder.
2022
First patient dosed in MM120 generalized-anxiety-disorder trial[4]Definium Therapeuticsen.wikipedia.org
Product launch · Product generation
The first participant entered MindMed’s Phase 2b study of MM120, later renamed DT120, for generalized anxiety disorder.
2021
MindMed completes HealthMode acquisition[4]Definium Therapeuticsen.wikipedia.org
Leadership change · M&A
MindMed closed its acquisition of digital-health startup HealthMode and appointed HealthMode chief executive Daniel Karlin as chief medical officer.
2021
Jamon Rahn leaves MindMed leadership[4]Definium Therapeuticsen.wikipedia.org
Leadership change
Co-founder Jamon Rahn stepped down as chief executive officer and as a director, with Robert Barrow taking over as chief executive.

Sources14 sources

Cite this profile: Cite the canonical profile. /brand-wiki/mindmed · Editorial policy · How profiles are compiled